142808-44-4

Basic information

• Product Name: 5'-O-(4,4'-dimethoxytrityl)-3'-O-(2-cyanoethyl-N,N'-diisopropylphosphoramidite)-N⁴-benzoyl-2'-deoxy-2',2'-difluorocytidine
• CAS NO: 142808-44-4
• Molecular Weight: 869.902
• Mol File: 142808-44-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5'-O-(4,4'-dimethoxytrityl)-3'-O-(2-cyanoethyl-N,N'-diisopropylphosphoramidite)-N⁴-benzoyl-2'-deoxy-2',2'-difluorocytidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5'-O-(4,4'-dimethoxytrityl)-3'-O-(2-cyanoethyl-N,N'-diisopropylphosphoramidite)-N⁴-benzoyl-2'-deoxy-2',2'-difluorocytidine(142808-44-4)
• EPA Substance Registry System: 5'-O-(4,4'-dimethoxytrityl)-3'-O-(2-cyanoethyl-N,N'-diisopropylphosphoramidite)-N⁴-benzoyl-2'-deoxy-2',2'-difluorocytidine(142808-44-4)

Safety Data

• Hazardous Substances Data: 142808-44-4(Hazardous Substances Data)

Upstream product

• 98-88-4 benzoyl chloride 
• 93-97-0 benzoic acid anhydride 
• 95058-81-4 gemcitabine 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 142816-70-4 N⁴-benzoyl-2'-deoxy-2',2'-difluorocytidine 
• 102691-36-1 N,N,N',N'-tetraisopropyl 2-cyanoethylphosphorodiamidite 
• 124482-92-4 2-cyanoethyl-N,N-(diisopropylamino)chlorophosphine 

Relevant articles and documents

Biological and physicochemical characterization of siRNAs modified with 2',2'-difluoro-2'-deoxycytidine (gemcitabine)

The use of synthetic short interfering RNAs (siRNAs) is currently a method of choice to manipulate gene expression in mammalian cells. Efforts aimed at improving siRNA biological activity, including increased silencing properties, higher substrate specifi

Targeting nano carrier bearing nucleoside anti-tumor drugs and preparation method and application thereof

The invention provides a targeting nano carrier bearing nucleoside anti-tumor drugs and preparation method and application thereof. The targeting nano carrier comprises DNA tetrahedron, Affibody molecule and nucleoside anti-tumor drugs. The preparation me

Novel oligonucleotides and related compounds

The present invention relates generally to oligonucleotides and more specifically to oligonucleotides which have a sequence including at least two CDG dinucleotides and a prodrug of an antimetabolite. The prodrug can be part of a CpG dinucleotide or may be attached elsewhere on the oligonucleotide.